07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps were...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis also said that NASDAQ initiated proceedings to delist the company due to its belief that Myrexis is a "public shell" and the resignation of all the company's independent directors. The company could not be...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

EpiCept, Myrexis deal

EpiCept said that Myrexis terminated a 2003 deal and returned rights to cancer compound Azixa verubulin to EpiCept. Myrexis discontinued development of Azixa last year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis said it would reduce headcount to 10 by June 30. The move follows a February announcement that the company retained Stifel Nicolaus Weisel to evaluate strategic alternatives and suspended development of all its preclinical...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis retained Stifel Nicolaus Weisel to evaluate strategic alternatives. Myrexis also suspended development of all its preclinical and clinical programs, including MPC-3100, a synthetic, non-geldanamycin inhibitor of heat shock protein 90 (Hsp90) in Phase...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis said it would restructure and reduce headcount by 15 (19%) to 62 after discontinuing development of Azixa verubulin earlier this year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb testing for...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Myrexis cancer, infectious news

Myrexis disclosed in its 4Q11 earnings ended June 30 that it is discontinuing development of Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer in Phase IIb testing for glioblastoma multiforme (GBM). According to the...
00:11 , Sep 10, 2011 |  BC Extra  |  Clinical News

Myrexis discontinues Azixa

Myrexis Inc. (NASDAQ:MYRX) said it will discontinue development of Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer in Phase IIb testing for glioblastoma multiforme (GBM). According to the company, completing the Phase IIb trial would...